» Articles » PMID: 2957611

The Combined Use of Positron Emission Tomography and DNA Polymorphisms for Preclinical Detection of Huntington's Disease

Overview
Journal Neurology
Specialty Neurology
Date 1987 Sep 1
PMID 2957611
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-three persons at risk for Huntington's disease (HD) have been studied using a polymorphic human linked DNA marker (D4S10) and positron emission tomography (PET). We determined the likelihood of inheritance of the gene for HD in 13 persons, using DNA polymorphism studies. Of these, eight persons had a greater than 90% probability of being presymptomatic heterozygotes for HD. Three of these eight subjects had caudate glucose utilization detected by PET that was more than 2 standard deviations (SD) below the age-matched control mean. Measurement of caudate glucose utilization in the other five presumed presymptomatic heterozygotes revealed results between 1 and 2 SD below the mean. Five persons had a less than 10% likelihood of having inherited the abnormal gene for HD. Of these, four had normal rates of glucose utilization in the caudate nuclei. However, one individual with DNA results indicating a low risk of developing HD had abnormally low measures of caudate glucose utilization. This suggests that a recombination had occurred between the linked marker and the gene in this person. These studies suggest that PET studies of caudate glucose utilization may help to confirm results of DNA studies in some persons, and may provide an opportunity to detect when DNA results may be incorrect due to recombination.

Citing Articles

Striatal hypometabolism in premanifest and manifest Huntington's disease patients.

Lopez-Mora D, Camacho V, Perez-Perez J, Martinez-Horta S, Fernandez A, Sampedro F Eur J Nucl Med Mol Imaging. 2016; 43(12):2183-2189.

PMID: 27349245 DOI: 10.1007/s00259-016-3445-y.


Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease.

Vittori A, Breda C, Repici M, Orth M, Roos R, Outeiro T Hum Mol Genet. 2014; 23(12):3129-37.

PMID: 24452335 PMC: 4030768. DOI: 10.1093/hmg/ddu022.


Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?.

Shin H, Kim M, Lee S, Lee K, Kim M, Kim J J Clin Neurol. 2013; 9(1):21-5.

PMID: 23346156 PMC: 3543905. DOI: 10.3988/jcn.2013.9.1.21.


Seeking brain biomarkers for preventive therapy in Huntington disease.

Esmaeilzadeh M, Ciarmiello A, Squitieri F CNS Neurosci Ther. 2010; 17(5):368-86.

PMID: 20553306 PMC: 6493912. DOI: 10.1111/j.1755-5949.2010.00157.x.


Functional imaging in Huntington's disease.

Paulsen J Exp Neurol. 2009; 216(2):272-7.

PMID: 19171138 PMC: 3810959. DOI: 10.1016/j.expneurol.2008.12.015.